IMR Press / EJGO / Volume 41 / Issue 3 / DOI: 10.31083/j.ejgo.2020.03.5051
Open Access Original Research
PTEN and CD146 expression in endometrioid adenocarcinoma
Show Less
1 Department of Gynecology and Obstetrics, Wuhan Asia General Hospital, Wuhan 430000, China
2 Department of Gynecology and Obstetrics, the First Affiliated Hospital of Yangzte University, Jingzhou 434000, China
Eur. J. Gynaecol. Oncol. 2020 , 41(3), 439–443; https://doi.org/10.31083/j.ejgo.2020.03.5051
Submitted: 10 October 2018 | Accepted: 10 January 2019 | Published: 15 June 2020
Abstract

Objective: Endometrioid adenocarcinoma is the most common pathological type of endometrial carcinoma. This study aimed to examine the expression of PTEN and CD146 in endometrioid adenocarcinoma, and to investigate their relationship with clinical characteristics of endometrioid adenocarcinoma. Materials and Methods: The expression of PTEN and CD146 in 126 specimens of endometrioid adenocarcinoma was detected by immunohistochemical technique, and the correlation of their expression with clinical parameters of the patients was analyzed. Results: PTEN expression in endometrioid adenocarcinoma group was lower than that in endometrial hyperplasia group and endometrial polyp group, while CD146 expression in endometrioid adenocarcinoma group was higher than that in endometrial hyperplasia group and endometrial polyp group (p < 0.05). High expression of CD146 was associated with his tological grade and depth of invasion of endometrioid adenocarcinoma, but there was no correlation between PTEN expression and clinical parameters. Conclusions: CD146 and PTEN may be promising biomarkers and targets for the diagnosis and treatment of endometrioid adenocarcinoma.

Keywords
Endometrioid adenocarcinoma
PTEN
CD146
Pathology
Figures
Figure 1.
Share
Back to top